EUVIMEDEUVIMED entdecken
Kohortenstudie

Incidence and Risk Factors for Invasive Mold Infections in Children During First-Line Chemotherapy for Primary Acute Leukemia: A National Retrospective Cohort Study

Inzidenz und Risikofaktoren invasiver Schimmelpilzinfektionen bei Kindern während der Erstlinien-Chemotherapie bei primärer akuter Leukämie: eine nationale retrospektive Kohortenstudie

Rasmus Moeller Duus iD, Emma Soendergaard Joergensen, Emil Bach Offendal, Nadja Hawwa Vissing, Kristian Loevvik Juul-Dam, Flemming Schoenning Rosenvinge iD, Dorthe Grosen, Nina Marie Birk, Katja Majlund Harder, Steffen Husby iD, Jesper Bonnet Moeller, Robin Christensen und 2 weitere

Journal of the Pediatric Infectious Diseases Society · 07.11.2026 · 15 (11)

DOI: 10.1093/jpids/piag112 ↗

Auf einen Blick

Bei 621 Kindern mit AML oder ALL traten während der Erstlinien-Chemotherapie 43 invasive Schimmelpilzinfektionen auf. Bei AML war das Risiko höher als bei ALL.

Fragestellung

Wie hoch sind Inzidenz, Zeitpunkt, Outcomes und mögliche behandlungsbezogene Risikofaktoren invasiver Schimmelpilzinfektionen bei Kindern mit AML oder ALL unter Erstlinien-Chemotherapie?

Methode

Retrospektive nationale Kohortenstudie aller Kinder <18 Jahre mit Erstlinien-Chemotherapie wegen AML oder ALL in Dänemark 2008-2022; Klassifikation nach 2020 EORTC/MSGERC; Analyse mit kumulativer Inzidenz, Cox-Regression und Kaplan-Meier.

Ergebnisse

43/621 (6,9 %) entwickelten eine IMI; 14/90 (15,6 %) bei AML und 29/531 (5,5 %) bei ALL. Adjustiert war AML mit höherem IMI-Risiko assoziiert als ALL (HR 5,6; 95 %-KI 2,6-12,1).

Schlussfolgerung der Autor:innen

In dieser nationalen Kohorte traten IMI häufiger auf als in vielen früheren pädiatrischen Studien, besonders bei AML. Die Infektionen wurden während der Erstlinien-Therapie beobachtet und waren mit relevanter Mortalität verbunden.

Kernaussagen

  • IMI bei 43 von 621 Kindern mit AML/ALL
  • AML: höheres Risiko als ALL (HR 5,6; 95 %-KI 2,6-12,1)
  • IMI traten über die gesamte Erstlinien-Therapie auf

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of the Pediatric Infectious Diseases Society, online erschienen am 16.10.2026. Verfasst von Rasmus Moeller Duus und 13 weiteren Autor:innen. Beteiligte Einrichtung: Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Invasive Fungal Infections, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit nennt 30 Literaturangaben. Gefördert von: University of Southern Denmark, Odense University Hospital Research Fund, Novo Nordisk Foundation.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Invasive mold infections (IMI) are life-threatening complications during treatment for pediatric acute leukemia. Population-based data on IMI incidence, timing, and outcomes during first-line therapy remain limited. We aimed to provide a nationwide epidemiological overview of IMI during first-line treatment of pediatric acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and explore potential treatment-related risk factors.

Methods

We conducted a retrospective nationwide cohort study of all children (<18 years) initiating first-line chemotherapy for AML or ALL in Denmark during 2008-2022. IMIs were classified as proven or probable according to 2020 European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium criteria by review of microbiology, imaging, pathology, and chart data. Follow-up covered first-line chemotherapy. Competing risk–adjusted cumulative incidence of IMI was estimated, risk factors were evaluated using Cox regression, and survival after IMI was analyzed using the Kaplan–Meier method.

Results

Among 621 patients, 43 (6.9%) developed IMI: 14/90 (15.6%) with AML and 29/531 (5.5%) with ALL. In adjusted Cox regression, AML was associated with higher IMI hazard than ALL (HR 5.6, 95% CI, 2.6-12.1), whereas no other prespecified risk factors were independently associated with IMI. Incidence rates were 38.6 per 100 patient-years in AML and 2.7 in ALL. Nearly half of IMIs occurred beyond 90 days after initiation of first-line chemotherapy. Four patients experienced a second distinct IMI episode; Aspergillus species accounted for 37 out of 47 (79%) episodes and non-Aspergillus molds for 10 out of 47 (21%). IMI-associated death occurred in 10 patients (1.6% of the cohort), yielding a case fatality rate of 23% among IMI cases; IMI was present in 43% of all deaths.

Conclusions

In this nationwide cohort, IMI occurred more frequently than reported in many previous pediatric studies, particularly in AML. IMIs were observed throughout first-line therapy, despite antifungal prophylaxis, and were associated with substantial mortality, emphasizing the need for sustained clinical vigilance beyond induction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteInvasive Fungal InfectionsPrecursor Cell Lymphoblastic Leukemia-LymphomaHumansRetrospective StudiesFemaleChildRisk FactorsIncidenceChild, PreschoolDenmarkMaleInfantAdolescent

Stichwörter der Autor:innen

acute lymphoblastic leukemiaacute myeloid leukemiacohort studyinvasive mold infectionpediatric leukemia

Autor:innen und Institutionen

  • Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark.
  • Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
  • Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark.
  • Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
  • Department of Clinical Microbiology, Odense University Hospital, Odense, Denmark.

ORCID-Profile: Rasmus Moeller Duus, Flemming Schoenning Rosenvinge, Steffen Husby, Mathias Rathe

Förderung

  • University of Southern Denmark
  • Odense University Hospital Research Fund
  • Novo Nordisk Foundation
  • Fonden til Lægevidenskabens Fremme
  • Danish Childhood Cancer Foundation
  • Oak Foundation

Zitieren

APA

Duus, R. M., Joergensen, E. S., Offendal, E. B., Vissing, N. H., Juul-Dam, K. L., Rosenvinge, F. S., Grosen, D., Birk, N. M., Harder, K. M., Husby, S., Moeller, J. B., Christensen, R., Duus, L. A., & Rathe, M. (2026). Incidence and Risk Factors for Invasive Mold Infections in Children During First-Line Chemotherapy for Primary Acute Leukemia: A National Retrospective Cohort Study. Journal of the Pediatric Infectious Diseases Society, 15(11). https://doi.org/10.1093/jpids/piag112

Vancouver

Duus RM, Joergensen ES, Offendal EB, Vissing NH, Juul-Dam KL, Rosenvinge FS, et al. Incidence and Risk Factors for Invasive Mold Infections in Children During First-Line Chemotherapy for Primary Acute Leukemia: A National Retrospective Cohort Study. Journal of the Pediatric Infectious Diseases Society. 2026;15(11). doi:10.1093/jpids/piag112

BibTeX
@article{Duus2026,
  author = {Duus, Rasmus Moeller and Joergensen, Emma Soendergaard and Offendal, Emil Bach and Vissing, Nadja Hawwa and Juul-Dam, Kristian Loevvik and Rosenvinge, Flemming Schoenning and Grosen, Dorthe and Birk, Nina Marie and Harder, Katja Majlund and Husby, Steffen and Moeller, Jesper Bonnet and Christensen, Robin and Duus, Louise Aarup and Rathe, Mathias},
  title = {Incidence and Risk Factors for Invasive Mold Infections in Children During First-Line Chemotherapy for Primary Acute Leukemia: A National Retrospective Cohort Study},
  journal = {Journal of the Pediatric Infectious Diseases Society},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.1093/jpids/piag112}
}
Kostenlos starten →